Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Innovotech Inc V.IOT

Innovotech Inc. is a Canada-based biotechnology company. The Company is engaged in owning intellectual property, conducting contract research, and owning and providing devices for testing in multiple applications in microbiology. Its contract research services include Antimicrobial Contract Research; Antimicrobial and Anti-Biofilm Agents, including Minimum Inhibitory Concentration (MIC) and... see more

TSXV:IOT - Post Discussion

Innovotech Inc > Insider Buying
View:
Post by overnout on Mar 09, 2021 9:52am

Insider Buying

Vancouver, British Columbia –TheNewswire -March8,2021– Alan C. Savage, Chief Financial Officer and Director of  Innovotech Inc. (the “Issuer”) announces that he has, directly or indirectly, acquired an additional 1,586,555 common shares, 264,027 common share purchase warrants, and 35,000 stock options (collectively, the “Acquired Securities”).

As of October 23, 2019, the date of Mr. Savage’s previous early warning report, Mr. Savage had beneficial ownership of, or direction or control over, 11,401,000 Common Shares and 75,000 incentive stock options, representing approximately 31.5% of the then-issued and outstanding Common Shares on an undiluted basis (or approximately 31.6% of the then-issued and outstanding Common Shares on a partially diluted basis).

Following the acquisition of the Acquired Securities and the exercise of certain existing stock options, Mr. Savage has beneficial ownership of, or direction or control over, an aggregate of 13,062,555 common shares, 264,027 common share purchase warrants and 35,000incentive stock options, representing in the aggregate approximately 34.12% of the outstanding common shares of the Issuer on non-diluted basis (or  34.63% on a partially diluted basis). This represents an increase of 2.62% in Mr. Savage’s ownership of common shares on an undiluted basis (or an increase of 3.03% on a partially diluted basis) since the date of Mr. Savage’s previous early warning report.

These securities were acquired pursuant to various transactions, including market purchases through the facilities of the TSX Venture Exchange, purchases in the context of a private placement of units completed by the Issuer on September 2, 2020, a grant of incentive stock options made by the Issuer on October 16, 2020, issuances of common shares upon the exercise of existing incentive stock options, and as consideration for the assignment on February 19, 2021 by Lonsdale Capital Corporation (“Lonsdale”) to the Issuer of an 8% convertible debenture issued by CanBiocin Inc. with a principal amount outstanding of $150,000. Lonsdale is a corporation owned and controlled by Mr. Savage.

Be the first to comment on this post